AbelZeta Announces Upcoming Oral Presentations at LUPUS 2025

AbelZeta Pharma, Inc. (PRNewsfoto/AbelZeta Pharma, Inc.)

  • Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy Targeting Lupus Nephritis, Systemic Lupus Erythematosus and Multiple Sclerosis 
  • Phase 1, First-in-Human Investigator-Initiated Trial (IIT)

ROCKVILLE, Md., May 22, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that data from its Phase 1 first-in-human investigator-initiated trial (IIT) of C-CAR168 study (NCT06249438, the "Study") has been published in an abstract shared in a podium presentation at the 16th International Congress on Systemic Lupus Erythematosus ("LUPUS 2025"), in Toronto, Canada. The Principal Investigator (PI) of the Study, Professor Nan Shen from Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, presented the early clinical results in patients with refractory autoimmune disease.

Recommended for you